Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in Chronic HFrEF Patients (China, Phase III)
CTR20171378Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dapagliflozin in heart failure with reduced ejection fraction (HFrEF), sponsored by AstraZeneca. Started Nov 2017; status: completed.
02
Drugs
dapagliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on CTR20171378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171378.